Related Experiment Video
Updated: Jan 31, 2026

Flow Cytometry Purification of Mouse Meiotic Cells
Published on: April 15, 2011
Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international
Stuart D Scott1,2, Matthew Fletcher1, Helen Whitehouse1
1UK NEQAS for Leucocyte Immunophenotyping, Sheffield Teaching Hospitals, Sheffield, UK.
Background:
Minimal/measurable residual disease (MRD) testing by flow cytometry (FC) has been proposed as a potential surrogate clinical endpoint in plasma cell myeloma (PCM) clinical trials. As a result, effort has gone into standardizing this approach on PCM patients.
Aims:
To assess inter-laboratory variation in FC MRD testing of PCM patients in an independent inter-laboratory study.
Methods:
A dilution series of five stabilized bone marrow samples manufactured to contain 0%, 0.1%, 0.01%, 0.001%, and 0.0001% neoplastic plasma cells (PCs) were tested blind, using standardized FC PCM MRD assays by 10 international laboratories.
Results:
Laboratories' assays broadly adhered to the consensus guidelines; however, some deviations were identified in panel design, fluorochrome conjugates, and lysis reagents. Despite this, all laboratories that returned results detected neoplastic PCs down to 0.001% of leucocytes. 6/8 laboratories detected neoplastic PCs at a level of 0.0001%. Quantitative data returned by laboratories showed good consensus and linearity with increasing variation at lower levels of MRD. However, examples of analytical and post analytical error were identified.
Summary/Conclusion:
Broadly standardized PCM MRD FC assays can attain the lower limit of detection (LOD) required by current and future clinical trials, an important consideration in establishing PCM MRD testing as a surrogate clinical marker in PCM clinical trials. Laboratories' assays showed good linearity, encouraging the prediction of survival based on log reduction in neoplastic PC populations in future clinical trials. However, the deviations from consensus guidelines identified in this study would suggest that if PCM MRD assays are further standardized interlaboratory variation could be reduced. © 2018 International Clinical Cytometry Society.
Insights
Standardized flow cytometry (FC) testing for minimal residual disease (MRD) in plasma cell myeloma (PCM) shows promise as a clinical endpoint. While generally accurate, further standardization can reduce inter-laboratory variation in MRD detection.
Area of Science:
- Hematology
- Clinical Cytometry
- Oncology
Background:
- Minimal/measurable residual disease (MRD) testing by flow cytometry (FC) is a potential surrogate endpoint for plasma cell myeloma (PCM) clinical trials.
- Standardization efforts are underway to refine FC MRD testing in PCM patients.
Purpose of the Study:
- To assess inter-laboratory variation in FC MRD testing for PCM patients.
- To evaluate the performance of standardized FC assays in detecting neoplastic plasma cells (PCs).
Main Methods:
- Ten international laboratories participated in a blind inter-laboratory study.
- A dilution series of bone marrow samples with known percentages of neoplastic PCs (0% to 0.0001%) were tested using standardized FC PCM MRD assays.
Main Results:
- Laboratories' assays generally adhered to consensus guidelines, with some deviations noted.
- All participating laboratories detected neoplastic PCs down to 0.001%, and most (6/8) detected them at 0.0001%.
- Quantitative data showed good consensus and linearity, though variation increased at lower MRD levels; analytical and post-analytical errors were identified.
Conclusions:
- Broadly standardized PCM MRD FC assays can achieve the required lower limit of detection for clinical trials.
- Assay linearity supports survival prediction based on PC reduction, but further standardization is needed to minimize inter-laboratory variation.
Related Concept Videos
Flow Cytometry
In...
Internal Receptors
Ready Mixed Concrete
Residual Plots
When the residual values are plotted against the variable x, it is called a residual...
Residual Stresses
Serum Laboratory Studies, Stool Test, Breath Test

